A phase II trial comparing dalpiciclib in combination with letrozole versus standard chemotherapy as neoadjuvant therapy in patients with high-risk HR- positive HER-2 negative breast cancer: ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback